![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
April 24, 2025
Posts
Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: https://bit.ly/EA4231 cc: @MelanicjMD, @theNCI, @UVACancerCenter
Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://bit.ly/ea8192-trial cc: @BladderCancerUS @JCensits @PGrivasMDPhD
Did you know July is #SarcomaAwarenessMonth?🎗️Take a moment to read our trial spotlight on EA7211/STRASS 2. This #clinicaltrial is the 2nd randomized study ever performed in retroperitoneal soft tissue #sarcoma. More: https://bit.ly/EA7211STRASS2-blog cc: @kencardonaMD, @richardriedelmd
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
38
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
